Tagged Articles

Merck 99 articles

Dismissed Fosamax bone fracture lawsuits revived by appeals court


About 5,000 lawsuits alleging femur fractures caused by Merck’s osteoporosis drug Fosamax that had been dismissed in federal and state courts were given new life when the U.S. Court of Appeals for the Third Circuit overturned the dismissal. The appeals court found that the District Court misapplied the U.S. Supreme Court’s 2009 ruling in Wyeth v. Levine, during which the Supreme Court held that state-law failure-to-warn claims are preempted when there is evidence that the Food and Drug Administration (FDA) would not have approved a warning label that those suing the drug company claim was necessary. In June 2014, U.S. ... Read More

Male pattern baldness meds allegedly taken by Trump linked to sexual side effects

male pattern baldness - Wikimedia commons

President Donald Trump takes a medication to treat male pattern baldness, his personal physician revealed, which is at the heart of a class action lawsuit over reported sexual side effects. The drug in question is Propecia, known chemically as finasteride and manufactured by Merck. Finasteride, under the brand name Proscar, was approved by the Food and Drug Administration (FDA) in 1992 to treat symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate. In 1997, the FDA approved finasteride, under the brand name Propecia, to include treatment for male pattern baldness. Both drugs are for men only. In ... Read More

New diabetes drug tested as an add-on in triple therapy


Merck and Pfizer are teaming up on a new type 2 diabetes treatment and if clinical trials continue to show promise, they hope to apply for Food and Drug Administration (FDA) approval by the end of the year. The experimental drug, ertugliflozin is in a class of type 2 diabetes drugs called sodium glucose cotransporter 2 (SGLT2) inhibitors, which also includes the brand names Invokana, Invokamet and Jardiance. SGLT2 inhibitors work to lower blood sugar levels by blocking the reabsorption of glucose in the kidneys, allowing more sugar to be excreted through the urine. Ertugliflozin improved glycemic control in type ... Read More

Merck gives up on experimental osteoporosis drug due to safety concerns


Merck’s experimental osteoporosis drug odanacatib showed that it was effective at preventing bone fractures, but put users at risk of atrial fibrillation and stroke. As a result, Merck said that the risks of the drug outweighed the benefits and thus they were officially giving up on the development of odanacatib. Atrial fibrillation is a quivering or irregular heartbeat that can lead to blood clots, strokes, heart failure, and other heart-related conditions. Two years ago, Merck announced it was delaying a filing with the Food and Drug Administration (FDA) after Phase III results raised cardiovascular safety concerns. The news was a blow ... Read More

FDA warns of dosing errors with antifungal drug Noxafil

Noxafil anti fungal

Reports of hospitalizations and a patient death related to dosing errors with the antifungal medication Noxafil (posaconazole) have prompted the Food and Drug Administration (FDA) to issue a Drug Safety Communication cautioning health care providers that there has been confusion with differences in dosing regimens between two oral formulations of the drug Noxafil. Noxafil is used to treat or prevent fungal infections such as Aspergillus and Candida, especially in people with weakened immune systems such as those undergoing chemotherapy, stem cell transplantation and those with HIV infections. It is also used to treat a fungal infection called thrush caused by ... Read More

Merck accused of FLSA violations; class action filed by plant employees


Merck & Co. Inc., the pharmaceutical giant responsible for drugs like Vioxx and Gardasil, is now the target of a proposed class and Fair Labor Standards Act (FLSA) collective action filed in New Jersey federal court. The suit claims the Merck employees were forced to labor at least 45 minutes prior to their normal shift daily without compensation. The 26 employees worked full time in the Rahway, N.J., “pilot plant” as research chemical operators (RCOs), some having been employed as early as 1995. Upon bringing the unpaid compensation issue up to the company, the complaint alleges Merck threatened their jobs and ... Read More

Four Dangerous Diabetes Drugs


Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

Whistleblowers accuse Merck of withholding, distorting mumps vaccine data


Two former Merck virologists who filed a whistleblower lawsuit against the pharmaceutical company alleging it falsified data so the U.S. government would buy its mumps vaccine are now also accusing the drug giant of dodging questions about the vaccine’s effectiveness. In a June 1 letter, Stephen A. Krahling and Joan A. Wlochowski, who filed the whistleblower suit against Merck & Co. under the federal False Claims Act, asked Pennsylvania federal judge Lynne A. Sitarski to force Merck to answer questions about the effectiveness of its mumps vaccine, saying the company is “hiding behind a facade of confusion and obfuscation” on ... Read More

Novartis settles lawsuit claiming osteoporosis drug caused jawbone decay


A lawsuit against the makers of the osteoporosis drug Zometa claiming the medication caused serious jawbone decay has been settled, just as a state appeals court was scheduled to rule whether to affirm or reverse the no-cause verdict won previously by Novartis Pharmaceuticals Corp., against the plaintiff. The terms of the agreement will not be disclosed. The lawsuit, filed by plaintiff Beverly Meng, was only the second to go to trial in New Jersey. Another 119 lawsuits in New Jersey name Novartis’ Zometa or the company’s other bone loss drug Aredia claiming jawbone injury are yet to be heard. The ... Read More

Lawsuits claim type 2 diabetes drugs caused pancreatic cancer

januvia - sitagliptin

Ann Falcone of Staten Island, NY is suing two different drug companies alleging their type 2 diabetes treatments caused her to develop pancreatic cancer. Falcone claims she began taking Januvia (sitagliptin) in July 2009 to help control her blood sugar levels. Januvia is a oral antihyperglycemic drug known as a dipeptiidyl peptidase-4, or DPP-4, inhibitor. In May 2011, her doctor also prescribed Victoza (liraglutide), an injectable long-acting glucagon-like peptide-1 agonist, or GLP-1 agonist. Both drugs are in a class of type 2 diabetes medications known as incretin mimetics. But a year after starting Victoza, Falcone was diagnosed with pancreatic cancer. It ... Read More